ORIC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
45.3M
+14.3%
39.6M
+14.7%
34.6M
-5.8%
36.7M
-6.1%
39.1M
R&D
36.3M
+15.5%
31.4M
+21.6%
25.9M
-10.1%
28.8M
-5.8%
30.5M
SG&A
9.0M
+10.0%
8.2M
-5.9%
8.7M
+10.1%
7.9M
-7.2%
8.5M
Operating Income
-45296000
-14.3%
-39619000
-14.7%
-34551000
+5.8%
-36671000
+6.1%
-39064000
EBITDA
-45032000
-14.4%
-39349000
-15.0%
-34231000
+5.9%
-36383000
+6.1%
-38754000
Net Income
-41492000
-16.0%
-35767000
-17.2%
-30505000
+6.4%
-32587000
+10.4%
-36355000
EPS (Basic)
$-0.38
-11.8%
$-0.34
-13.3%
$-0.30
+9.1%
$-0.33
+29.8%
$-0.47
EPS (Diluted)
$-0.38
-11.8%
$-0.34
-13.3%
$-0.30
+9.1%
$-0.33
+29.8%
$-0.47
Shares (Diluted)
108.0M
+2.4%
105.5M
+2.3%
103.1M
+4.1%
99.0M
+26.7%
78.1M
Oric Pharmaceuticals (ORIC) โ€” Financials